Related Experiment Videos
Primary and secondary prevention of arterial thromboembolism
1Center for Molecular and Vascular Biology, University of Leuven, Belgium.
Insights
Daily aspirin is recommended for cardiovascular disease prevention in high-risk individuals and after myocardial infarction. Antiplatelet agents like aspirin and ticlopidine are crucial for preventing thrombosis after grafts and angioplasty.
Area of Science:
- Cardiology
- Vascular Medicine
- Pharmacology
Background:
- Cardiovascular diseases, including myocardial infarction and stroke, remain leading causes of morbidity and mortality.
- Antiplatelet agents and anticoagulants are cornerstones in the prevention and management of thrombotic events.
- Optimal therapeutic strategies require careful consideration of drug class, patient risk, and clinical indication.
Purpose of the Study:
- To review the evidence for aspirin and other antiplatelet agents in the primary and secondary prevention of cardiovascular and cerebrovascular events.
- To compare the efficacy and safety of aspirin with other antithrombotic therapies, including oral anticoagulants and ticlopidine.
- To provide guidance on the appropriate use of these agents in various clinical scenarios, such as angina, post-myocardial infarction, valve replacement, and arterial disease.
Main Methods:
- Systematic review of existing literature on aspirin, ticlopidine, dipyridamole, and oral anticoagulants.
- Analysis of clinical trial data and observational studies evaluating the efficacy and safety of these agents.
- Evidence-based guideline synthesis for antithrombotic therapy in diverse cardiovascular conditions.
Main Results:
- Aspirin (approximately 300 mg/day) is recommended for primary prevention of myocardial infarction in high-risk individuals (male and female).
- Aspirin or ticlopidine is indicated for unstable angina and post-coronary angioplasty to prevent reocclusion; aspirin is also effective for aorto-coronary grafts.
- Oral anticoagulants remain essential for synthetic cardiac valve prostheses, with aspirin or dipyridamole potentially reducing intensity; diuretics are preferred for hypertensive stroke prevention, with aspirin considered for high-risk elderly.
Conclusions:
- Aspirin is a valuable and convenient agent for primary and secondary prevention of cardiovascular and cerebrovascular events in specific patient populations.
- Antiplatelet agents, particularly aspirin and ticlopidine, demonstrate significant efficacy in preventing thrombosis in arterial grafts and after angioplasty.
- The choice of antithrombotic therapy should be individualized based on cardiovascular risk, specific clinical indication, and potential bleeding risk.
Abstract:
Aspirin in doses of approximately 300 mg/day may be recommended for the primary prevention of myocardial infarction in males and probably also in females, but only in those individuals with a moderate to high risk of cardiovascular disease. In patients with stable angina, aspirin decreases the risk for a first myocardial infarction. Aspirin or ticlopidine should be given to patients with unstable angina, in conjunction with heparin in the most severe cases. Long-term oral anticoagulant treatment after myocardial infarction in low risk patients has a limited effect on mortality but reduces the incidence of non-fatal recurrent myocardial infarction and stroke. Daily aspirin is more convenient and simple, and is at least as effective, but associated with a lower risk of bleeding. The concurrent use of aspirin and low intensity anticoagulation in the secondary prevention of myocardial infarction has, however, not been investigated. Various antiplatelet agents, including aspirin (alone or combined with dipyridamole) and ticlopidine, have, in contrast to oral anticoagulants, proved useful in the prevention of early thrombosis in aorto-coronary grafts, provided treatment begins at the latest 6 h after surgery. The usefulness of antiplatelet drugs has been well established in the prevention of immediate reocclusion following coronary angioplasty, but so far no drugs can prevent late restenosis. In patients with a synthetic cardiac valve prosthesis, lifelong treatment with coumarins is still indispensable, but their antithrombotic effect can be reinforced by dipyridamole or aspirin which also allows to reduce the intensity of anticoagulation. In uncomplicated bioprosthetic valve replacement, low intensity anticoagulation during the first 3 months suffices. Diuretics probably provide the best primary protection against cerebrovascular accidents in moderate hypertensives, although medium doses of aspirin may be considered in elderly people at high risk of such accidents. Aspirin (alone or combined with dipyridamole) and ticlopidine may be recommended for the secondary prevention of cerebral ischaemic accidents. Aspirin and ticlopidine, but not oral anticoagulants, reinforce the treatment of obliterative arterial disease in the lower limbs.